AVITA Medical Hits a Tipping Point: Cash Flow Breakeven in Sight
Revenue crosses $20M, guidance raised, and reimbursement clarity sets stage for 2027
RCEL · Earnings Call · 2026-08-06
The Quarter That Changed the Narrative
AVITA Medical (RCEL) reported a transformative second quarter. Revenue reached $21.7 million, up 18% year-over-year and 13% sequentially, the first time the company has crossed the $20 million quarterly threshold. Management raised full-year revenue guidance to $86-$89 million (20-24% growth), and more importantly, introduced new guidance for cash flow breakeven and cash generation during the fourth quarter of 2026. (“we delivered strong revenue growth in the second quarter of $21.7 million, up 18% year over year and 13% sequentially” — Cary G. Vance, President and Chief Executive Officer · 2026-08-06) The quarter underscores a broader theme: sequential growth is becoming a consistent pattern. After two consecutive quarters of meaningful sequential growth (9.7% and 13%), CFO David O'Toole highlighted the driving forces: scaling revenue, a gross margin above 81%, and disciplined control of operating expenses. (“net cash use improved to approximately $3.2 million during the quarter, representing a major improvement from the first quarter and from the quarterly cash burn each quarter last year” — David O'Toole, Chief Financial Officer · 2026-08-06) This is a clear inflection point for a company that has heavily burned cash for years.Reimbursement Reset: Simplicity and Certainty
A key shift is the transition to Category I CPT codes for skin cell suspension autograft (SCSA), effective January 1, 2027. The current 8-code structure based on harvest, preparation, and application will be replaced by a simplified 4-code family. Management expects this to reduce coding complexity and bring physician reimbursement under a nationally published RVU framework, improving transparency. As CEO Cary Vance explained: (“the biggest problem last year was confusion. And the amount of time that it took from our salespeople and our customers to try and get a handle on if they were going to get paid, what they were going to get paid, and when” — Cary G. Vance, President and Chief Executive Officer · 2026-08-06) The reimbursement turbulence of 2025 had been a major overhang, and its resolution plus simplification is a structural tailwind.The Path to Cash Generation
The company is also benefiting from operating leverage. Despite launching newer products (Cohealyx, PermeaDerm), gross margin reached 81.9% in Q2, a testament to the pricing power and cost discipline that underpins the path to breakeven. Operating expenses remained flat sequentially and down 6% year-over-year. David O'Toole noted: (“those trends give us increasing confidence that AVITA is approaching an important financial inflection point” — David O'Toole, Chief Financial Officer · 2026-08-06) The balance sheet still carries leverage, but the improved cash flow trajectory suggests the risk is decreasing.Market Reaction and Outlook
The market is taking notice. RCEL has surged roughly 100% in the last 90 days, reflecting optimism about the updated guidance and durability of the reimbursement fix. Yet, challenges remain: the company still has a net loss, and execution on VAC reviews and international expansion is early. Prior calls have shown a consistent narrative: growth across the portfolio and manufacturing efficiencies. (“We grew in RECELL and we grew in Cohealyx. Those are the 2 main drivers.” — Cary Vance, President and Chief Executive Officer · 2026-05-14) And the company has been patiently working through the MAC labyrinth. (“we are highly engaged with all seven, and we expect that they will publish as well.” — Cary Vance, Executive · 2026-02-12)Essentially, we are spending less money to run the business, and collecting cash faster from our operations. Taken together, those trends give us increasing confidence that AVITA is approaching an important financial inflection point.